The British pharmaceutical company, GlaxoSmithKline (GSK), has completed the acquisition of the American company Tesaro, which manufactures onco drugs. The deal value exceeded $5 billion. The information was announced in December 2018. GlaxoSmithKline believes that the deal will strengthen the pharmaceutical business and expand the prospects for cancer treatment. Tesaro President, Mary Lynn Hadley, expects that the purchase of GSK will help extend the life of many cancer patients and continue the company's development and commercialization initiatives.
London Stock Exchange agrees to sell Borsa Italiana to Euronext for $5 billion07.10.2020
Trump demands Congress to give $25 billion in cash assistance for American airlines02.10.2020
Goldman Sachs to purchase General Motors’ credit card business worth $2.5 billion01.10.2020
Rolls-Royce plans to raise $6.5 billion to cope with a "worst-case scenario" amid the coronavirus crisis